BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

«Lamivudine

Below is an extended Lamivudine research listing. Click here to return to the Lamivudine main in depth entry.

Recent Publications on Lamivudine:

Supportive Role Played by Precore and PreS2 Genomic Changes in the Establishment of Lamivudine-Resistant Hepatitis B Virus.
Background. @nbsp; Hepatitis B virus (HBV) establishes lamivudine...
Direct Link
21st August, 2008
1Department of Gastroenterology and Hepatology, Osaka University Graduate
Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B. 19th August, 2008
Department of Gastroenterology, Ajou University School of Medicine,
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand.
Coinfection with human immunodeficiency virus (HIV) and hepatitis B virus...
Direct Link
13th August, 2008
National Centre in HIV Epidemiology and Clinical Research, University of
Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Hyperexpression of the programmed death 1 (PD-1) molecule is a hallmark of...
Direct Link
13th August, 2008
Institute of Hepatology, University College London, London, United
Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. 12th August, 2008
Hepatobiliary Pancreatic Surgery Center, First Affiliated Hospital,
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
CONTEXT: The availability of new antiretroviral drugs and formulations,...
Direct Link
12th August, 2008
Division of Infectious Diseases, Columbia University College of Physicians
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
OBJECTIVES: This study evaluated the effects of 3 class-sparing...
Direct Link
9th August, 2008
Infection Prevention and Clinical Epidemiology Unit, University of
Antiviral Effect of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate, Adminstered Orally Alone and in Combination, to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection.
Adefovir dipivoxil (ADV) and tenofovir disoproxil fumarate (TDF) are...
Direct Link
5th August, 2008
Gastrointestinal Unit, Department of Clinical Sciences, College of
Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches.
The indications for liver transplantation among patients with...
Direct Link
5th August, 2008
Department of Surgery-Transplantation Service, Catholic University-"A.
Clinical drugs that interact with St. John's wort and implication in drug development. 5th August, 2008
Divison of Chinese Medicine, School of Health Sciences, RMIT University,
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. 5th August, 2008
Clinic for Infectious Diseases and Tropical Medicine, University of
Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial. 5th August, 2008
NSERM U912 'Economic Et Social Sciences, Health Systems Et Societies',
Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. 5th August, 2008
Institute of Digestive Disease, The Chinese University of Hong Kong, Hong
A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. 5th August, 2008
Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische
Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis. 5th August, 2008
NTU Center for Genomic Medicine, National Taiwan University College of
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional